kobe2602Ras inhibitor CAS# 454453-49-7 |
- Elacridar
Catalog No.:BCC1546
CAS No.:143664-11-3
- Elacridar hydrochloride
Catalog No.:BCC1547
CAS No.:143851-98-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 454453-49-7 | SDF | Download SDF |
PubChem ID | 3827738 | Appearance | Powder |
Formula | C14H9F4N5O4S | M.Wt | 419.31 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 14.3 mg/mL (34.10 mM; Need ultrasonic and warming) | ||
Chemical Name | 1-[2,6-dinitro-4-(trifluoromethyl)anilino]-3-(4-fluorophenyl)thiourea | ||
SMILES | C1=CC(=CC=C1NC(=S)NNC2=C(C=C(C=C2[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-])F | ||
Standard InChIKey | NNPBSITXCGPXJC-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C14H9F4N5O4S/c15-8-1-3-9(4-2-8)19-13(28)21-20-12-10(22(24)25)5-7(14(16,17)18)6-11(12)23(26)27/h1-6,20H,(H2,19,21,28) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | kobe2602 is a novel and effective small-molecule compound inhibiting Ras–Raf interaction by SBDD; exhibits potent activity to competitively inhibit the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 149 ± 55 μM.
IC50 value: 149 ± 55 uM (Ki) [1]
Target: Ras-Raf
These two compounds(Kobe0065 and Kobe2602), added to the culture medium at 2 and 20 μM, effectively reduced the amount of c-Raf-1 associated with H-Ras G12V in NIH 3T3 cells in a dose-dependent manner, indicating the inhibition of the cellular activity of Ras. A rough estimate of the IC50 value for the cellular Ras–Raf-binding inhibition was around 10 μM (Fig. 1B), which was not much different from the Ki values for the in vitro Ras–Raf-binding inhibition considering thequite low cellular concentration of Raf. A similar inhibitory effect was also observed with NIH 3T3 cells overexpressing K-Ras G12V. Both Kobe0065 and Kobe2602 at 20 μM efficiently inhibited the phosphorylation of MEK and ERK, downstream kinases of Raf in NIH 3T3 cells transiently expressing
H-Ras G12V, although the effect was slightly weaker than that of
2 μM sorafenib. References: |
kobe2602 Dilution Calculator
kobe2602 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.3849 mL | 11.9244 mL | 23.8487 mL | 47.6974 mL | 59.6218 mL |
5 mM | 0.477 mL | 2.3849 mL | 4.7697 mL | 9.5395 mL | 11.9244 mL |
10 mM | 0.2385 mL | 1.1924 mL | 2.3849 mL | 4.7697 mL | 5.9622 mL |
50 mM | 0.0477 mL | 0.2385 mL | 0.477 mL | 0.9539 mL | 1.1924 mL |
100 mM | 0.0238 mL | 0.1192 mL | 0.2385 mL | 0.477 mL | 0.5962 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Kobe2602 is a small-molecule inhibitor of Ras with Ki value of 149 μM [1].
Kobe2602 is a compound screened out by a computer-assisted search of about 160,000 compounds. It dose-dependently inhibited the binding of H-RasG12V to c-Raf-1 in NIH 3T3 cells with a rough IC50 value of 10 μM. 20 μM of Kobe2602 effectively suppressed the phosphorylation of down-stream kinases of Raf, including MEK and ERK. Besides that, in NIH 3T3 cells transfected with H-rasG12V, Kobe2602 inhibited the colony formation with IC50 value of 1.4 μM. Kobe2602 also showed effect on other cancer cells carrying activated ras oncogenes, such as PANC-1(K-rasG12V), HT1080 (N-rasQ61L) and HCT116 (H-rasG13D). Moreover, in mice bearing SW480 xenografts, administration of Kobe2602 resulted in 40-50% inhibition of the tumor growth at dose of 80 mg/kg [1].
References:
[1] Shima F, Yoshikawa Y, Ye M, et al. In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras–effector interaction. Proceedings of the National Academy of Sciences, 2013, 110(20): 8182-8187.
- Nudifloside D
Catalog No.:BCN7005
CAS No.:454212-54-5
- PSB 11 hydrochloride
Catalog No.:BCC7239
CAS No.:453591-58-7
- Motesanib
Catalog No.:BCC1776
CAS No.:453562-69-1
- Saprirearine
Catalog No.:BCN3980
CAS No.:453518-30-4
- Boc-Gly-OH
Catalog No.:BCC3396
CAS No.:4530-20-5
- Boc-DL-Phe-OH
Catalog No.:BCC3434
CAS No.:4530-18-1
- GW788388
Catalog No.:BCC3666
CAS No.:452342-67-5
- SU14813 double bond Z
Catalog No.:BCC1972
CAS No.:452105-23-6
- Boc-N-Me-Val-OH
Catalog No.:BCC3357
CAS No.:45170-31-8
- AV-412
Catalog No.:BCC5119
CAS No.:451493-31-5
- AV-412 free base
Catalog No.:BCC5120
CAS No.:451492-95-8
- 10-Hydroxydihydroperaksine
Catalog No.:BCN5502
CAS No.:451478-47-0
- Acetophenone tosylhydrazone
Catalog No.:BCC8804
CAS No.:4545-21-5
- Corosolic acid
Catalog No.:BCN5503
CAS No.:4547-24-4
- Grossamide K
Catalog No.:BCC4547
CAS No.:
- 4-Benzoyl-3-methyl-1-phenyl-5-pyrazolone
Catalog No.:BCC8695
CAS No.:4551-69-3
- Isovouacapenol C
Catalog No.:BCN6557
CAS No.:455255-15-9
- Zaurategrast
Catalog No.:BCC2070
CAS No.:455264-31-0
- H-Glu(OBzl)-OBzl.HCl
Catalog No.:BCC2927
CAS No.:4561-10-8
- Neocnidilide
Catalog No.:BCN8174
CAS No.:4567-33-3
- 3-Benzyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride
Catalog No.:BCC8625
CAS No.:4568-71-2
- 5-O-Methylgenistein
Catalog No.:BCN7714
CAS No.:4569-98-6
- 1alpha, 24, 25-Trihydroxy VD2
Catalog No.:BCC1298
CAS No.:457048-34-9
- Pyridone 6
Catalog No.:BCC1874
CAS No.:457081-03-7
In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction.[Pubmed:23630290]
Proc Natl Acad Sci U S A. 2013 May 14;110(20):8182-7.
Mutational activation of the Ras oncogene products (H-Ras, K-Ras, and N-Ras) is frequently observed in human cancers, making them promising anticancer drug targets. Nonetheless, no effective strategy has been available for the development of Ras inhibitors, partly owing to the absence of well-defined surface pockets suitable for drug binding. Only recently, such pockets have been found in the crystal structures of a unique conformation of RasGTP. Here we report the successful development of small-molecule Ras inhibitors by an in silico screen targeting a pocket found in the crystal structure of M-RasGTP carrying an H-Ras-type substitution P40D. The selected compound Kobe0065 and its analog kobe2602 exhibit inhibitory activity toward H-RasGTP-c-Raf-1 binding both in vivo and in vitro. They effectively inhibit both anchorage-dependent and -independent growth and induce apoptosis of H-ras(G12V)-transformed NIH 3T3 cells, which is accompanied by down-regulation of downstream molecules such as MEK/ERK, Akt, and RalA as well as an upstream molecule, Son of sevenless. Moreover, they exhibit antitumor activity on a xenograft of human colon carcinoma SW480 cells carrying the K-ras(G12V) gene by oral administration. The NMR structure of a complex of the compound with H-RasGTP(T35S), exclusively adopting the unique conformation, confirms its insertion into one of the surface pockets and provides a molecular basis for binding inhibition toward multiple RasGTP-interacting molecules. This study proves the effectiveness of our strategy for structure-based drug design to target RasGTP, and the resulting Kobe0065-family compounds may serve as a scaffold for the development of Ras inhibitors with higher potency and specificity.
Discovery of small-molecule Ras inhibitors that display antitumor activity by interfering with Ras.GTP-effector interaction.[Pubmed:25034098]
Enzymes. 2013;34 Pt. B:1-23.
Ras proteins, particularly their active GTP-bound forms (Ras.GTP), were thought "undruggable" owing to the absence of apparent drug-accepting pockets in their crystal structures. Only recently, such pockets have been found in the crystal structures representing a novel Ras.GTP conformation. We have conducted an in silico docking screen targeting a pocket in the crystal structure of M-Ras(P40D).GTP and obtained Kobe0065, which, along with its analogue kobe2602, inhibits binding of H-Ras.GTP to c-Raf-1. They inhibit the growth of H-rasG12V-transformed NIH3T3 cells, which are accompanied by downregulation of not only MEK/ERK but also Akt, RalA, and Sos, indicating the blockade of interaction with multiple effectors. Moreover, they exhibit antitumor activity on a xenograft of human colon carcinoma carrying K-rasG12V. The nuclear magnetic resonance structure of a complex of the compound with H-Ras(T35S).GTP confirms its insertion into the surface pocket. Thus, these compounds may serve as a novel scaffold for the development of Ras inhibitors with higher potency and specificity.